265 related articles for article (PubMed ID: 22586157)
1. Clinical and pathological significance of interleukin 6 overexpression in systemic sclerosis.
Khan K; Xu S; Nihtyanova S; Derrett-Smith E; Abraham D; Denton CP; Ong VH
Ann Rheum Dis; 2012 Jul; 71(7):1235-42. PubMed ID: 22586157
[TBL] [Abstract][Full Text] [Related]
2. Increased serum pentraxin 3 in patients with systemic sclerosis.
Iwata Y; Yoshizaki A; Ogawa F; Komura K; Hara T; Muroi E; Takenaka M; Shimizu K; Hasegawa M; Fujimoto M; Takehara K; Sato S
J Rheumatol; 2009 May; 36(5):976-83. PubMed ID: 19273457
[TBL] [Abstract][Full Text] [Related]
3. A possible contribution of visfatin to the resolution of skin sclerosis in patients with diffuse cutaneous systemic sclerosis via a direct anti-fibrotic effect on dermal fibroblasts and Th1 polarization of the immune response.
Masui Y; Asano Y; Shibata S; Noda S; Akamata K; Aozasa N; Taniguchi T; Takahashi T; Ichimura Y; Toyama T; Sumida H; Yanaba K; Tada Y; Sugaya M; Sato S; Kadono T
Rheumatology (Oxford); 2013 Jul; 52(7):1239-44. PubMed ID: 23443327
[TBL] [Abstract][Full Text] [Related]
4. Decreased interleukin-20 expression in scleroderma skin contributes to cutaneous fibrosis.
Kudo H; Jinnin M; Asano Y; Trojanowska M; Nakayama W; Inoue K; Honda N; Kajihara I; Makino K; Fukushima S; Ihn H
Arthritis Rheumatol; 2014 Jun; 66(6):1636-47. PubMed ID: 24470401
[TBL] [Abstract][Full Text] [Related]
5. Increased Serum Levels of the IL-33 Neutralizing sST2 in Limited Cutaneous Systemic Sclerosis.
Wagner A; Köhm M; Nordin A; Svenungsson E; Pfeilschifter JM; Radeke HH
Scand J Immunol; 2015 Sep; 82(3):269-74. PubMed ID: 26095613
[TBL] [Abstract][Full Text] [Related]
6. Serum levels, tissue expression and cellular secretion of macrophage migration inhibitory factor in limited and diffuse systemic sclerosis.
Corallo C; Paulesu L; Cutolo M; Ietta F; Carotenuto C; Mannelli C; Romagnoli R; Nuti R; Giordano N
Clin Exp Rheumatol; 2015; 33(4 Suppl 91):S98-105. PubMed ID: 26005773
[TBL] [Abstract][Full Text] [Related]
7. Clinical significance of serum soluble Tie1 levels in patients with systemic sclerosis.
Noda S; Asano Y; Aozasa N; Akamata K; Taniguchi T; Takahashi T; Ichimura Y; Toyama T; Sumida H; Kuwano Y; Yanaba K; Tada Y; Sugaya M; Kadono T; Sato S
Arch Dermatol Res; 2013 May; 305(4):325-31. PubMed ID: 23233281
[TBL] [Abstract][Full Text] [Related]
8. Clinical subsets, skin thickness progression rate, and serum antibody levels in systemic sclerosis patients with anti-topoisomerase I antibody.
Perera A; Fertig N; Lucas M; Rodriguez-Reyna TS; Hu P; Steen VD; Medsger TA
Arthritis Rheum; 2007 Aug; 56(8):2740-6. PubMed ID: 17665460
[TBL] [Abstract][Full Text] [Related]
9. Effect of granulocyte macrophage-colony stimulating factor on extracellular matrix deposition by dermal fibroblasts from patients with scleroderma.
Postiglione L; Ladogana P; Montagnani S; di Spigna G; Castaldo C; Turano M; Bruno EM; Di Meglio F; Riccio A; Rossi G
J Rheumatol; 2005 Apr; 32(4):656-64. PubMed ID: 15801021
[TBL] [Abstract][Full Text] [Related]
10. Progranulin Overproduction Due to Fli-1 Deficiency Contributes to the Resistance of Dermal Fibroblasts to Tumor Necrosis Factor in Systemic Sclerosis.
Ichimura Y; Asano Y; Akamata K; Noda S; Taniguchi T; Takahashi T; Toyama T; Tada Y; Sugaya M; Sato S; Kadono T
Arthritis Rheumatol; 2015 Dec; 67(12):3245-55. PubMed ID: 26245842
[TBL] [Abstract][Full Text] [Related]
11. Association of C-reactive protein with high disease activity in systemic sclerosis: results from the Canadian Scleroderma Research Group.
Muangchan C; Harding S; Khimdas S; Bonner A; ; Baron M; Pope J
Arthritis Care Res (Hoboken); 2012 Sep; 64(9):1405-14. PubMed ID: 22556030
[TBL] [Abstract][Full Text] [Related]
12. Increased serum soluble CD40 levels in patients with systemic sclerosis.
Komura K; Fujimoto M; Matsushita T; Yanaba K; Kodera M; Kawasuji A; Hasegawa M; Takehara K; Sato S
J Rheumatol; 2007 Feb; 34(2):353-8. PubMed ID: 17295440
[TBL] [Abstract][Full Text] [Related]
13. Enhanced expression of ephrins and thrombospondins in the dermis of patients with early diffuse systemic sclerosis: potential contribution to perturbed angiogenesis and fibrosis.
Avouac J; Clemessy M; Distler JH; Gasc JM; Ruiz B; Vacher-Lavenu MC; Wipff J; Kahan A; Boileau C; Corvol P; Allanore Y
Rheumatology (Oxford); 2011 Aug; 50(8):1494-504. PubMed ID: 21454305
[TBL] [Abstract][Full Text] [Related]
14. Different contributions of angiostatin and endostatin in angiogenesis impairment in systemic sclerosis: a cohort study.
Almeida I; Oliveira Gomes A; Lima M; Silva I; Vasconcelos C
Clin Exp Rheumatol; 2016; 34 Suppl 100(5):37-42. PubMed ID: 26885625
[TBL] [Abstract][Full Text] [Related]
15. Chemokine receptor CCR2 expression by systemic sclerosis fibroblasts: evidence for autocrine regulation of myofibroblast differentiation.
Carulli MT; Ong VH; Ponticos M; Shiwen X; Abraham DJ; Black CM; Denton CP
Arthritis Rheum; 2005 Dec; 52(12):3772-82. PubMed ID: 16320328
[TBL] [Abstract][Full Text] [Related]
16. Cartilage oligomeric matrix protein expression in systemic sclerosis reveals heterogeneity of dermal fibroblast responses to transforming growth factor beta.
Farina G; Lemaire R; Pancari P; Bayle J; Widom RL; Lafyatis R
Ann Rheum Dis; 2009 Mar; 68(3):435-41. PubMed ID: 18408251
[TBL] [Abstract][Full Text] [Related]
17. Thymic stromal lymphopoietin is up-regulated in the skin of patients with systemic sclerosis and induces profibrotic genes and intracellular signaling that overlap with those induced by interleukin-13 and transforming growth factor β.
Christmann RB; Mathes A; Affandi AJ; Padilla C; Nazari B; Bujor AM; Stifano G; Lafyatis R
Arthritis Rheum; 2013 May; 65(5):1335-46. PubMed ID: 23335246
[TBL] [Abstract][Full Text] [Related]
18. Distinct expression of adhesion molecules on skin fibroblasts from patients with diffuse and limited systemic sclerosis. A pilot study.
Iannone F; Matucci-Cerinic M; Falappone PC; Guiducci S; Cinelli M; Distler O; Lapadula G
J Rheumatol; 2005 Oct; 32(10):1893-8. PubMed ID: 16206343
[TBL] [Abstract][Full Text] [Related]
19. Simultaneous inhibition of c-Abl and Src kinases abrogates the exaggerated expression of profibrotic genes in cultured systemic sclerosis dermal fibroblasts.
Piera-Velazquez S; Jimenez SA
Clin Exp Rheumatol; 2018; 36 Suppl 113(4):36-44. PubMed ID: 30277861
[TBL] [Abstract][Full Text] [Related]
20. State-of-the-art technologies provide new insights linking skin and blood vessel abnormalities in SSc-related disorders.
Dinsdale G; Wilkinson S; Wilkinson J; Moore TL; Manning JB; Berks M; Marjanovic E; Dickinson M; Herrick AL; Murray AK
Microvasc Res; 2020 Jul; 130():104006. PubMed ID: 32320708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
